Phenomic AI Launches with $6 Million Financing and an AI/ML Platform for Targeting the Tumor Stroma
Retrieved on:
Wednesday, October 7, 2020
The financing was led by CTI Life Sciences Fund and joined by AV8 Ventures, Luminous Ventures, and Viva BioInnovator.
Key Points:
- The financing was led by CTI Life Sciences Fund and joined by AV8 Ventures, Luminous Ventures, and Viva BioInnovator.
- Ruchita Sinha, General Partner at AV8, further commented, In two years, the Phenomic team has made impressive progress in building their platform and using it to find new drug targets in the tumor stroma.
- The appointments of Mike, Jim, and Pam, leaders in immuno-oncology, further highlight the exceptional advancements of Phenomic.
- Weve rapidly identified novel targets in the tumor stroma and have confirmed that they are heavily upregulated in specific solid tumors.